Xarelto is a ground breaking new factor Xa inhibitor, developed by Bayer healthcare. Belonging to a group of medicines called anticoagulants, it works by blocking the blood clotting factor Xa and thereby reduces the tendency of the blood to form clots.
Modern, impactful and memorable, Xarelto resonates with prescribers and patients alike and helps to re-enforce the key brand message.
In recent news the FDA has approved Bayer/J&J’s Xarelto®, a once-daily pill for stroke prevention in patients with an abnormal heart rhythm. Developed by Origin the name is derived from Factor Xa, has a modern/dynamic look and feel, suggesting a rapid onset of action, superior treatment and prevention.
It is a significant approval from the US regulator with this being the second licence, increasing the lifespan of the brand and potentially increasing its value as it is anticipated that it will generate more sales than its first indication, as there are many more AF patients with a high stroke risk.